Physician profile
Scott Marsel
NPI 1811942048
$9,817.97
in general payments reported to CMS, 2019-2025
35 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $649 · 2021: $1,460 · 2022: $1,122 · 2023: $1,776 · 2024: $1,436 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,970.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,790.76 | 2019-2025 | |
| Novo Nordisk INC | $951.84 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $641.85 | 2021-2025 | |
| Lilly USA, LLC | $573.53 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $452.45 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $449.88 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $415.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.37 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $291.93 | 2019-2023 | |
| Exact Sciences Corporation | $276.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $272.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $206.16 | 2019-2025 | Capvaxive |
| Kowa Pharmaceuticals America, INC. | $137.39 | 2019-2022 | |
| Abbott Laboratories | $131.99 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.67 | 2019-2025 | Xifaxan |
| Dynavax Technologies Corporation | $102.99 | 2022-2025 | Heplisav-B |
| Axonics, INC. | $90.41 | 2022 | |
| Esperion Therapeutics, INC. | $88.95 | 2021 | |
| Daiichi Sankyo INC. | $67.48 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $57.87 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $55.40 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $50.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $42.69 | 2019-2020 | |
| Averitas Pharma INC. | $40.11 | 2023-2024 | Qutenza |
| Sanofi Pasteur INC. | $32.02 | 2020-2023 | |
| Astellas Pharma US INC | $27.22 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $24.20 | 2024 | Inspire |
| Ibsa Pharma INC. | $22.99 | 2022 | |
| Gilead Sciences, INC. | $19.69 | 2025 | |
| Antares Pharma, INC. | $17.73 | 2019 | |
| Neuronetics, INC. | $16.26 | 2020 | |
| Allergan, INC. | $15.81 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.45 | 2023 | Quviviq |
| Aytu Biopharma, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Marsel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.